NCT06291207View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-224

PHASE3RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Hypertension,Essential
Interventions
DRUG

AD-224A

PO, Once daily, 8weeks

DRUG

AD-224B

PO, Once daily, 8weeks

DRUG

AD-224C

PO, Once daily, 8weeks

DRUG

Placebo of AD-224A

PO, Once daily, 8weeks

DRUG

Placebo of AD-224B

PO, Once daily, 8weeks

DRUG

Placebo of AD-224C

PO, Once daily, 8weeks

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY